
|Articles|November 21, 2014
Convection-Enhanced Delivery of Nanoliposomal Irinotecan for Recurrent Glioblastoma or High-Grade Glioma
Author(s)Nicholas Butowski, MD
Nicholas Butowski, MD, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.
Advertisement
Clinical Pearls
Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.
- 1-3 catheters co-deliver liposomal-irinotecan and gadolinium into a patient’s tumor.
- Gadolinium is used so that imaging can be done in real-time.
- This process is unique because it bypasses systemic toxicity and ensures that the drug is administered properly.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































